Oncology Hematology Care Inc. (Kenwood)

Cincinnati, OH

Sorting 1 by

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Myeloma Service
  • 23-182